The U.S. dietary supplement industry commends the Food and Drug Administration (FDA) for taking action to protect consumers by calling out marketers who make illegal and unsubstantiated drug claims related to COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. In February, the industry issued strong warning to companies and consumers to avoid marketing or using dietary supplements that are presented as treating, curing or preventing COVID-19.
The U.S. Food and Drug Administration (FDA) convened a teleconference meeting on March 18 (FDA Briefing for Foods Stakeholders on Coronavirus Disease 2019 (COVID-19)), which was attended by AHPA president Michael McGuffin and by representatives of AHPA’s general counsel, Kleinfeld, Kaplan & Becker, LLP.
In a series of three letters to federal, state, and local governments, AHPA joined healthcare and food organizations to request that uniform language be included in shelter-at-home orders that provide direction to employees working in various industries related to dietary supplements, healthcare, and pharmaceuticals.
Due to overwhelming demand, AHPA is presenting a second, expanded Hemp-CBD Supplement Congress to provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market. Location and online platform have yet to be determined
AHPA has compiled answers to frequently asked questions and resources to help prepare for and respond to COVID-19. This page will be revised and updated regularly as new information about the novel coronavirus (SARS-CoV-2) and possible impacts on the herbal products industry and the people who work in this trade becomes available.
2020 Annual Fund Sponsors
AHPA appreciates the support of its sponsors, but does not endorse, recommend, or provide a warranty for any sponsor company, its products or services. AHPA has no responsibility for any transaction entered into with any of these companies.